Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.

Authors:
Birte Arlt Christin Zasada Katharina Baum Jasmin Wuenschel Guido Mastrobuoni Marco Lodrini Kathy Astrahantseff Annika Winkler Johannes H Schulte Sabine Finkler Martin Forbes Patrick Hundsdoerfer Dennis Guergen Jens Hoffmann Jana Wolf Angelika Eggert Stefan Kempa Hedwig E Deubzer

Int J Cancer 2021 Mar 17;148(5):1219-1232. Epub 2020 Dec 17.

Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

Here we sought metabolic alterations specifically associated with MYCN amplification as nodes to indirectly target the MYCN oncogene. Liquid chromatography-mass spectrometry-based proteomics identified seven proteins consistently correlated with MYCN in proteomes from 49 neuroblastoma biopsies and 13 cell lines. Among these was phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in de novo serine synthesis. MYCN associated with two regions in the PHGDH promoter, supporting transcriptional PHGDH regulation by MYCN. Pulsed stable isotope-resolved metabolomics utilizing C-glucose labeling demonstrated higher de novo serine synthesis in MYCN-amplified cells compared to cells with diploid MYCN. An independence of MYCN-amplified cells from exogenous serine and glycine was demonstrated by serine and glycine starvation, which attenuated nucleotide pools and proliferation only in cells with diploid MYCN but did not diminish these endpoints in MYCN-amplified cells. Proliferation was attenuated in MYCN-amplified cells by CRISPR/Cas9-mediated PHGDH knockout or treatment with PHGDH small molecule inhibitors without affecting cell viability. PHGDH inhibitors administered as single-agent therapy to NOG mice harboring patient-derived MYCN-amplified neuroblastoma xenografts slowed tumor growth. However, combining a PHGDH inhibitor with the standard-of-care chemotherapy drug, cisplatin, revealed antagonism of chemotherapy efficacy in vivo. Emergence of chemotherapy resistance was confirmed in the genetic PHGDH knockout model in vitro. Altogether, PHGDH knockout or inhibition by small molecules consistently slows proliferation, but stops short of killing the cells, which then establish resistance to classical chemotherapy. Although PHGDH inhibition with small molecules has produced encouraging results in other preclinical cancer models, this approach has limited attractiveness for patients with neuroblastoma.

Download full-text PDF

 Source
http://dx.doi.org/10.1002/ijc.33423DOI Listing
March 2021

Publication Analysis

Top Keywords

mycn-amplified cells
16
phgdh knockout
12
phgdh
10
diploid mycn
8
cells diploid
8
small molecules
8
serine glycine
8
inhibition small
8
mycn-amplified neuroblastoma
8
novo serine
8
serine synthesis
8
phosphoglycerate dehydrogenase
8
mycn
7
cells
7
mycn-amplified
6
pools proliferation
4
proliferation cells
4
nucleotide pools
4
proliferation stops
4
starvation attenuated
4

Altmetric Statistics


Show full details
2 Total Shares
2 Tweets
2 Citations

Similar Publications

Low Expression of IL-15 and NKT in Tumor Microenvironment Predicts Poor Outcome of MYCN-Non-Amplified Neuroblastoma.

Authors:
Yu-Mei Liao Tsai-Hsien Hung John K Tung John Yu Ya-Ling Hsu Jung-Tung Hung Alice L Yu

J Pers Med 2021 Feb 13;11(2). Epub 2021 Feb 13.

Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan.

Immune tumor microenvironment (TME) in neuroblastoma (NBL) contributes to tumor behavior and treatment response. T cells and natural killer (NK) cells have been shown to play important roles in the neuroblastoma TME. However, few reports address the clinical relevance of natural killer T cells (NKTs) and interleukin-15 (IL-15), one of the crucial cytokines controlling the activation and expansion of NK/NKT cells, in NBL. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.

Authors:
Atsuko Nakazawa

Pathol Int 2021 Mar 3. Epub 2021 Mar 3.

Department of Clinical Research, Saitama Children's Medical Center, Saitama, Japan.

The International Neuroblastoma Pathology Classification (INPC), which distinguishes a favorable histology (FH) and an unfavorable histology (UH), is one of the most powerful prognostic factors in patients with neuroblastoma. FH that shows spontaneous regression or age-appropriate tumor differentiation/maturation, is common in infants and has mutual interaction with Schwann cells via the NGF/NTRK1 pathway and gain of whole chromosome 17. In contrast, UH is prevalent in older children and is molecularly heterogeneous. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

GAS7 Deficiency Promotes Metastasis in MYCN-driven Neuroblastoma.

Authors:
Zhiwei Dong Kok Siong Yeo Gonzalo Lopez Cheng Zhang Erin N Dankert Eggum Jo Lynne Rokita Choong Yong Ung Taylor M Levee Zuag Paj Her Cassie J Howe Xiaonan Hou Janine H van Ree Shuai Li Shuning He Ting Tao Karen Fritchie Jorge Torres-Mora Julia S Lehman Alexander Meves Gina L Razidlo Komal S Rathi S John Weroha A Thomas Look Jan M van Deursen Hu Li Jennifer J Westendorf John M Maris Shizhen Zhu

Cancer Res 2021 Feb 18. Epub 2021 Feb 18.

Department of Biochemistry and Molecular Biology, Mayo Clinic

One of the greatest barriers to curative treatment of neuroblastoma (NB) is its frequent metastatic outgrowth prior to diagnosis, especially in cases driven by amplification of the MYCN oncogene. However, only a limited number of regulatory proteins that contribute to this complex MYCN-mediated process have been elucidated. Here we show that the growth arrest-specific 7 (GAS7) gene, located at chromosome band 17p13. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells.

Authors:
Reine Hanna Jad Abdallah Tamara Abou-Antoun

Front Oncol 2020 25;10:624560. Epub 2021 Jan 25.

School of Pharmacy, Lebanese American University, Byblos, Lebanon.

Background: Neuroblastoma is the most common pediatric extra-cranial nervous system tumor, originating from neural crest elements and giving rise to tumors in the adrenal medulla and sympathetic chain ganglia. Amplification of MYCN confers increased malignancy and poorer prognosis in high-risk neuroblastoma. Our SILAC proteomics analysis revealed over-expression of HSP90 in MYCN-amplified IMR-32 compared to the non-MYCN amplified SK-N-SH human neuroblastoma cells, rendering them highly resistant to therapeutic intervention. Read More

View Article and Full-Text PDF
January 2021
Similar Publications

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma.

Authors:
Barbara Marengo Alessandra Pulliero Maria Valeria Corrias Riccardo Leardi Emanuele Farinini Gilberto Fronza Paola Menichini Paola Monti Lorenzo Monteleone Giulia Elda Valenti Andrea Speciale Patrizia Perri Francesca Madia Alberto Izzotti Cinzia Domenicotti

J Pers Med 2021 Feb 7;11(2). Epub 2021 Feb 7.

Department of Experimental Medicine, University of Genova, 16100 Genova, Italy.

Neuroblastoma (NB) accounts for about 8-10% of pediatric cancers, and the main causes of death are the presence of metastases and the acquisition of chemoresistance. Metastatic NB is characterized by amplification that correlates with changes in the expression of miRNAs, which are small non-coding RNA sequences, playing a crucial role in NB development and chemoresistance. In the present study, miRNA expression was analyzed in two human -amplified NB cell lines, one sensitive (HTLA-230) and one resistant to Etoposide (ER-HTLA), by microarray and RT-qPCR techniques. Read More

View Article and Full-Text PDF
February 2021
Similar Publications